A comprehensive review of the shared roles of inflammatory cytokines in osteoporosis and cardiovascular diseases as two common old people problem; actions toward development of new drugs

International Journal of Pharmacology

Volumn 7, Issue 5, 2011, Pages 552-567

  Salari, Pooneh ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Cytokine; Osteoporosis; Oxidative stress; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; C REACTIVE PROTEIN; CATHEPSIN K; CLOPIDOGREL; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHYTOESTROGEN; PROSTAGLANDIN E2; TICLOPIDINE; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BONE METABOLISM; BONE REMODELING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ESTROGEN DEFICIENCY; FOAM CELL; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; SECONDARY HYPERPARATHYROIDISM; T LYMPHOCYTE; VITAMIN D INTOXICATION; VITAMIN K DEFICIENCY;

EID: 79960887964     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2011.552.567     Document Type: Review

References (195)

1. Abdollahi, M., A. Ranjbar, S. Shadnia, S. Nikfar and A. Rezaie, 2004. Pesticides and oxidative stress: A review. Med. Sci. Monit., 10: 141-147.
2. Abdollahi, M., B. Larijani, R. Rahimi and P. Salari, 2005. Role of oxidative stress in osteoporosis. Therapy, 2: 787-796.
3. Abedin, M., Y. Tintut and L.L. Demer, 2004. Vascular calcification: Mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol., 24: 1161-1170.
4. Abidgaard, N., J. Rungby, H. Glerup, K. Brixen and M. Kassem et al., 1998. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur. J. Haematol., 61: 128-134.
5. Abrahamsen, B., V. Bonnevie-Nielsen, E.N. Ebbesen, J. Gram and H. Beck-Nielsen, 2000. Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1 receptor antagonist: The Danish Osteoporosis Prevention Study. J. Bone. Miner. Res., 15: 1545-1554.
6. Amano, S., K. Naganuma, Y. Kawata, K. Kawakami, S. Kitano and S. Hanazawa, 1996. Prostaglandin E2 stimulates osteoclast formation via endogenous IL-1 β expressed through protein kinase A. J. Immunol., 156: 1931-1936.
7. Anand, D.V., A. Lahiri, E. Lim, D. Hopkins and R. Corder, 2006. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J. Am. Coll. Cardiol., 47: 1850-1857.
8. Aoyagi, K., P.D. Ross, J. Orloff, J.W. Davis, H. Katagiri and R.D. Wasnich, 2001. Low bone density is not associated with aortic calcification. Calcif. Tissue. Int., 69: 20-24.
9. Banks, L.M., B. Lees, J.E. MacSweeney and J.C. Stevenson, 1994. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: Links between osteoporosis and cardiovascular disease. Eur. J. Clin. Invest., 24: 813-817.
10. Barengolts, E.I., M. Beπnan, S.C. Kukreja, T. Kouznetsova, C. Lin and E.V. Chomka, 1998. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif. Tissue Int., 62: 209-213.
11. Barton, B.E., 1996. The biological effects of interleukin 6. Med. Res. Rev., 1: 87-109.
12. Bennermo, M., C. Held, S. Stemme, C.G. Ericsson, A. Silveira, F. Green and P. Tornvall, 2004. Genetic predisposition of the interleukin-6 response to inflammation: Implications for a variety of major diseases. Clin. Chem., 50: 2136-2140.
13. Bergstrom, J.D., R.G. Bostedor, P.J. Masarachia, A.A. Reszka and G. Rodan, 2000. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys., 373: 231-241.
14. Bertolini, D.R., G.E. Nedwin, T.S. Bπngman, D.D. Smith and G. R Mundy, 1986. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature, 319: 516-518.
15. Bhupathiraju, S.N., D.L. Alekel, J.W. Stewart, L.N. Hanson and K.M. Shedd et al., 2007. Relatioship of circulating total homocysteien and C-reactive protein to trabecular bone in postmenopausal women. J. Clin. Densitom., 10: 395-403.
16. Bidder, M., J.S. Shao, N. Charlton-Kachigian, A.P. Loewy, C.F. Semenkovich and D.A. Towler, 2002. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatoiy factor and activator protein-1 activities. J. Biol. Chem., 277: 44485-44496.
17. Blake, G.J., N. Rifai, J.E. During and P.M. Ridker, 2003. Blood pressure, C-reactive protein and risk of future cardiovascular events. Circulation, 108: 2993-2999.
18. Boukhris, R. and K.L. Becker, 1972. Calcification of the aorta and osteoporosis. A roentgenographic study. J. Am. Med. Assco., 219: 1307-13011.
19. Boyle, W.J., W.S. Simonet and D.L. Lacey, 2003. Osteoclast differentiation and activation. Nature, 423: 337-342.
20. Bruunsgaard, H., P. Skinhoj, A.N. Pedersen, M. Schroll and B.K. Pedersen, 2000. Aging, tumor necrosis factor-alpha (TNF-α) and atherosclerosis. Clin. Exp. Immunol., 121: 255-260.
21. Bucay, N., I. Sarosi, C.R. Dunstan, S. Morony and J. Tarpley et al., 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes. Dev., 12: 1260-1268.
22. Bui, Q., M. Prempeh and R. Wilensky, 2009. Atherosclerotic plaque development. Int. J. Biochem. Cell. Biol., 41: 2109-2113.
23. Bustamante, M., F. Diaz, M. Munoz, H.J. Gross and C.I. Rivas et al., 2007. Oxidized low density lipoproteins induce apoptosis inhuman lymphocytes: Involvement of mitogen-activated protein kinases. Cell. Mol. Biol., 53: OL954-OL964.
24. Caspar-Bauguil, S., J. Tkaczuk, M.J. Haure, M. Durand and J. Alcouffe et al., 1999. Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor K binding to DNA in activated T-lymphocytes. Biochem. J., 337: 269-274.
25. Cenci, S., G. Toraldo, M.N. Weitzmann, C. Roggia and Y. Gao et al., 2003. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II trans activator. Proc. Natl. Acad. Sci. USA., 100: 10405-10410.
26. Cesari, M., B.W. Penninx, A.B. Newman, S.B. Kritchevsky and B J. Nicklas et al., 2003. Inflammatory markers and onset of cardiovascular events: Results from the health ABC study. Circulation, 108: 2317-2322.
27. Chapman, C.M., J.P. Beilby, S.E. Humphries, L.J. Palmer, P.L. Thompson and J. Hung, 2003. Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population. Eur. Heart. J., 24: 1494-1499.
28. Chen, T.G., J.Z. Chen and X.D. Xie, 2006. Effect of aspirin on number, activity and inducible nitric oxide synthase of endothelial progenitor cells from peripheral blood. Acta. Pharmacol. Sin., 27: 430-436.
29. Chen, X.P., T.T. Zhang and G.H. Du, 2007. Lectm-like oxidized low-density lipoprotein receptor-1: A new promising target for the therapy of atherosclerosis. Cardiovasc. Drug. Rev., 25: 146-161.
30. Cohen-Solal, M.E., A.M. Graulet, M.A. Denne, J. Gueris, D. Baylink and M.C. de Vernejoul, 1993. Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: Involvement of cytokines. J. Clin. Endocrinol. Metab., 77: 1648-1653.
31. Colleselli, D., K. Bijuklic, B.A. Mosheimer and C.M. Kahler, 2006. Inhibition of cyclooxygenase (cox)-2 affects endothelial progenitor cell proliferation. Exp. Cell. Res., 312: 2933-2941.
32. Dayer, J.M. and E. Choy, 2010. Therapeutic targets in rheumatoid arthritis: The interleukin-6 receptor. Rheumatology, 49: 15-24.
33. De Martinis, M., M.C. Di Benedetto, L.P. Mengoli and L. Ginaldi, 2006. Senile osteoporosis: Is it an immune-mediated disease?. Inflamm. Res., 55: 399-404.
34. Demer, L.L., 2002. Vascular calcification and osteoporosis: Inflammatory responses to oxidized lipids. Int. J. Epidemiol., 31: 737-741.
35. Devlin, J., J. Lilley, A. Gough, A. Huissoon and R. Holder et al., 1996. Clinical associations of dual-energy X-ray absorptimetry measurement of hand bone mass in rheumatoid arthritis. Br. J. Rheumatol., 35: 1256-1262.
36. Dhore, C.R., J.P. Cleutijens, E. Lutgens, K.B. Cleutjens and P.P. Geusens et al., 2001. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol., 221: 1998-2003.
37. Ding, C., V. Parameswaran, R. Udayan, J. Burgess and G. Jones, 2008. Circulating levels of inflammatoiy markers predict change in bone mineral density and resorption in older adults: A longitudinal study. J. Clin Endocrinol. Metab., 93: 1952-1958.
38. Edwards, C.J., D.J. Hart and T.D. Spector, 2000. Oral statins and increased bone mineral density in postmenopausal women. Lancet, 355: 2218-2219.
39. Faccio, R., S. Takeshita, A. Zallone, F.P. Ross and S.L. Teitelbaum, 2003. c-FMS and the v 3 integrin collaborate during osteoclast differentiation. J. Clin. Invest., III: 749-758.
40. Farhat, G.N., E.S. Strotmeyer, A.B. Newman, K. Sutton-Tyrrell and D.C. Bauer et al., 2006. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging and body composition study. Calcif. Tissue. Int., 79: 102-111.
41. Farhat, G.N., A.B. Newman, K.S. Sutton-Tyrrell, K.A. Matthews and R. Boudreau et al., 2007. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos. Int., 18: 999-1008.
42. Ferrari, S.L., L. Ahn-Luong, P. Garnero, S.E. Humphries and S.L. Greenspan, 2003. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J. Clin. Endocrinol. Metab., 88: 255-259.
43. Frost, M.L., R. Grella, S.C. Millasseau, B.Y. Jiang, G. Hampson, I. Fogelman, P.J. Chowienczyk, 2008. Relationship of calcification of atherosclerosis plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif. Tissue. Int., 83: 112-120.
44. Fukunaga, M., N. Makita, L.J. Roberts, J.D. Morrow, K. Takahashi and K.F. Badr, 1993. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol., 264: C1619-C1624.
45. Ganesan, K., S. Teklehaimanot, T.H. Tran, M. Asuncion and K. Norris, 2005. Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J. Nat. Med. Assoc., 97: 329-333.
46. Gao, Y., F. Grassi, M. Robbie, M. Terauchi and K. Page et al., 2007. IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest., 117: 122-132.
47. Gaspard, U.J., J.M. Gottal and F.A. van den Brule, 1995. Postmenopausal changes of lipid and glucose metabolism: A review of their main aspects. Maturiras, 21: 171-178.
48. Gasparyan, A.Y., T. Watson and G. Y. Lip, 2008. The role of aspirin in cardiovascular prevention: Implications of aspirin resistance. J. Am. Coll. Cardiol., 51: 1829-1843.
49. Gasparyan, A.Y., A. Stavropoulos-Kalinoglou, D.P. Mikhailidis and K.M. Douglas, 2010. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol. Int., 31: 153-164.
50. Gerrity, R.G. and H.K. Naito, 1980. Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. Artery., 8: 208-214.
51. Giachelli, C.M., N. Bae, M. Almeida, D.T. Denhardt, C.E. Alpers and S.M. Schwartz, 1993. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest., 92: 1686-1696.
52. Giuliani, N., M. Pedrazzoni, G. Passeri and G. Girasole, 1998. Biphosphonates inhibits IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol., 27: 38-41.
53. Glass, C.K. and J.L. Witztum, 2001. Atherosclerosis: The road ahead. Cell, 104: 503-516.
54. Gniwotta, C., J.D. Morrow, L.J. Roberts and H. II, Kuhn, 1997. Prostaglandin F2-like compounds, F2-Isoprostanes are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc. Biol., 17: 3236-3241.
55. Gowen, M. and G.R. Mundy, 1986. Actions of recombinant interleukin 1, interleukin 2 and interferon-gamma on bone resorption in vitro. J. Immunol., 136: 2478-2482.
56. Graham, L.S., F. Parhami, Y. Tintut, C.M.R. Kitchen, L.L. Demer L and R.B. Effros, 2009. Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss. Clin. Immunol., 133: 265-275.
57. Hak, A.E., H.A. Pols, A.M. van Hemert, A. Hofman and J.C. Witteman, 2000. Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arterioscler. Thromb. Vasc. Biol., 20: 1926-1931.
58. Harris, T.B., L. Ferrucci, R.P. Tracy, M.C. Corti and S. Wacholder et al., 1999. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med., 106: 506-512.
59. Hasani-Ranjbar, S., B. Larijani and M. Abdollahi, 2009. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm. Allergy Drug Targets, 8: 2-10.
60. Hasani-Ranjbar, S., N. Nayebi, L. Moradi, A. Mehri, B. Larijani and M. Abdollahi, 2010. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia: A systematic review. Curr. Pharm. Des., 16: 2935-2947.
61. Hirose, K.I., H. Tomiyama, R. Okazaki, T. Arai and Y. Koji et al., 2003. Increased pulse wave velocity associated with reduced calcaneal quantitative osteo-sono index: Possible relationship between atherosclerosis and osteopenia. J. Clin. Endocrinol. Metab., 88: 2573-2578.
62. Hjortnaes, J., J. Butcher, J.L. Figueiredo, M. Riccio and R.H. Kohler et al., 2010. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodeling: A role for inflammation. Eur. Heart. J., 31: 1975-1984.
63. Hofbauer, L.C., C. Shui, B.L. Riggs, C.R. Dunstan, T.C. Spelsberg, T. O'Brien and S. Khosla, 2001. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res. Common., 280: 334-339.
64. Hofbauer, L.C., C.C. Brueck, C.M. Shanahan, M. Schoppet and H. Dobnig, 2007. Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporosis. Int., 18: 251-259.
65. Hu, Z., F. Zhang, Z. Yang, J. Zhang and D. Zhang, 2008. Low-dose aspirin promotes endothelial progenitor cell migration and adhesion and prevents sensecnce. Cell. Biol. Int., 32: 761-768.
66. Hyder, J.A., M.A. Allison, M.H. Criqui and C.M. Wright, 2007. Association between systemic calcified atherosclerosis and bone density. Calcif. Tissue. Int., 80: 301-306.
67. Imams hi, R., S. Seto, G. Toda, M. Yoshida and A. Ohtsuru et al., 2004. High brachial-ankle pulse wave velocity in an independent predictor of the presence of coronary artery disease in men. Hypertens. Res., 27: 71-78.
68. Jayalath, R.W., S.H. Mangan and J. Golledge, 2005. Aortic calcification. Eur. J. Vasc. Endovasc. Surg., 30: 476-488.
69. Jenny, N.S., R.P. Tracy, M.S. Ogg, le A. Luong and L.H. Kuller et al., 2002. In the elderly, interleukin-6 plasma levels and the-174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 22: 2066-2071.
70. Jie, K.S.G., M.L. Bots, C. Vermeer, J.C.M. Witteman and D.E. Grobbee, 1996. Vitamin K status and bone mass in women with and without aortic atherosclerosis: A population-based study. Calcif. Tissue. Int., 59: 352-356.
71. Jono, S., Y. Ikari, A. Shioi, K. Mori, T. Miki, K. Hara and Y. Nishizawa, 2002. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 106: 1192-1194.
72. Jorgensen, L., O. Joakimsen, G.K. Rosvold Berntsen, I. Heuch and BK. Jacobsen, 2004. Low bone mineral density is related to echogenic carotid arteiy plaques: A population-based study. Am. J. Epidemiol., 160: 549-556.
73. Jormsjo, S., D.M. Wuttge, A. Sirsjo, C. Whatling, A. Hamsten, S. Stemme and P. Eriksson, 2002. Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol., 161: 939-945.
74. Kadoglou, N.P.E., T. Gerasimidis, S. Golemati, A. Kapelouzou, P.E. Karayannacos and C.D. Liapis, 2008. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J. Vasc. Surg., 47: 55-62.
75. Kajbaf, F., M. Mojtahedzadeh and M. Abdollahi, 2007. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Therapy, 4: 97-106.
76. 2 stimulates osteoclast-like cell formation and bone-res orbing activity via osteoblasts: Role of cAMP-dependent protein kinase. J. Bone. Miner. Res., 11: 62-71.
77. Kania, D.M., N. Binkley, M. Checovich, T. Havighurst, M. Schilling and W.B. Ershler, 1995. Elevated plasma levels of in postmenopausal women do not correlate with bone density. J. Am. Geriatr. Soc., 43: 236-239.
78. Khosla, S., J.M. Peterson, K. Egan, J.D. Jones and B.L. Riggs, 1994. Circulation cytokine levels in osteoporotic and normal women. J. Clin. Endocrinol. Metab., 79: 707-711.
79. Khovidhunkit, W., M.S. Kim, R.A. Memon, J.K. Shigenaga, A.H. Moser, K.R. Feingold and C. Grunfeld, 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res., 45: 1169-1196.
80. Kiechl, S., G. Schett, G. Wenmng, K. Redlich and M. Oberhollenzer et al., 2004. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 109: 2175-2180.
81. Kiel, D.P., L.I. Kauppila, L.A. Cupples, M.T. Hannan, C.J. O'Donnell and P.W. Wilson, 2001. Bone loss and the progression of abdominal aortic calcification over a 25-year period: The Framingham heart study. Calcif. Tissue. Int., 68: 271-276.
82. Kim, S.M., J. Lee, O.H. Ryu, K.W. Lee and H.Y. Kim et al., 2005. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin. Endocrinol., 63: 594-598.
83. Kim, B.J., Y.M. Yu, E.N. Kim, Y.E. Chung, J.M. Koh and G.S. Kim, 2007. Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre-and postmenopausal women. Clin. Endocrinol., 67: 152-158.
84. Koh, J.M., Y.H. Khang, C.H. Jung, S. Bae, D.J. Kim, Y.E. Chung and G.S. Kim, 2005. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre-and postmenopausal women: Evidence for a link between systemic inflammation and osteoporosis. Osteoporosis Int., 16: 1263-1271.
85. Kong, Y.Y., U. Feige, I. Sarosi, B. Bolon and A. Tafuri et al., 1999. Activated T cells regulate bone loss and joint destruction in adjuant arthritis through osteoprotegerin ligand. Nature, 402: 304-309.
86. Krabbe, K.S., M. Pedersen and H. Bruunsgaard, 2004. Inflammatoiy mediators in the elderly. Exp. Gerontol., 39: 687-699.
87. Lacativa, P.G. and M.L. Farias, 2010. Osteoporosis and inflammation. Arq. Bras. Endocrinol. Metab., 54: 123-132.
88. Lawson, J.A., J. Rokach and G.A. FitzGerald, 1999. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem., 274: 24441-24444.
89. Liu, J., G.K. Sukhova, J.S. Sun, W.H. Xu, P. Libby and G.P. Shi, 2004. Lysosomal cysteine proteases in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 24: 1359-1366.
90. Liu, T.Z., A. Stern and J.D. Morrow, 1998. The isoprostanes: unique bioactive products of lipid peroxidation. An overview. J. Biomed. Sci., 5: 415-420.
91. Luckman, S.P., D.E. Hughes, F.P. Coxon, R.G.G. Russell and M.J. Rogers, 1998. Nitrogen-containing biphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J. Bone Mineral Res., 13: 581-589.
92. Lusis, A. J., R. Mar and P. Pajukanta, 2004. Genetics of atherosclerosis. Annu. Rev. Genomics. Hum. Genet., 5: 189-218.
93. Lynn, H., T. Kwok, S.Y.S. Wong, J. Woo and P.C. Leung, 2006. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone, 38: 584-588.
94. MacDonald, A.G., G. Birkinshaw, B. Durham, R.C. Bucknall and W.D. Fraser, 1997. Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br. J. Rheumatol., 36: 50-53.
95. Mangiafico, R.A., E. Russo, S. Riccobene, P. Pennisi, M. Mangiafico, F. D'Amico and C.E. Fiore, 2006. Increased prevalence of peripheral arterial disease in osteoporotic postmenopausal women. J. Bone Miner. Metab., 24: 125-131.
96. Manolagas, S.C., 2000. Birth and death of bone cells: Basic regulatory mechanism and implications for the pathogenesis and treatment of osteoporosis. Endocrinol. Rev., 21: 115-137.
97. Manolagas, S.G. and R.L. Jilka, 1995. Mechanisms of disease: Bone marrow, cytokines and bone remodeling-emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med., 332: 305-311.
98. Marhoffer, W., H. Stracke, I. Masoud, M. Scheja, V. Graef, W. Bolten and K. Federlin, 1995. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann. Rheum. Dis., 54: 556-559.
99. Matsuzaki, K., N. Udagawa, N. Takahashi, K. Yamaguchi and H. Yasuda et al., 1998. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun., 246: 199-204.
100. McFarlane, S.I., R. Muniyappa, J.J. Shin, G. Bahtiyar and J.R. Sowers, 2004. Osteoporosis and cardiovascular disease: Brittle bones and boned arteries, is there a link. Endocrine, 23: 1-10.
101. McKane, W.R., S. Khosla, J. Risteli, S.P. Robins, J.M. Muhs and B.L. Riggs, 1997. Role of estrogen deficiency in pathogenesis of secondary hyperparathyroidism and increased bone resorption in elderly women. Proc. Assoc. Am. Phys., 109: 174-180.
102. McKane, W.R., S. Khosla, J.M. Peterson, K. Egan and B.L. Riggs, 1994. Circulating levels of cytokines that modulate bone resorption: Effects of age and menopause in women. J. Bone. Miner. Res., 9: 1313-1318.
103. Mikhaylova, L., J. Malmquist and M. Nurminskaya, 2007. Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a. Calcif. Tissue. Int., 81:372-381.
104. Miyaura, C., K. Kusano, T. Masuzawa, O. Chaki and Y. Onoe et al., 1995. Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6. J. Bone. Miner. Res., 10: 1365-1373.
105. Montalcini, T., V. Emanuele, R. Ceravolo, G. Gorgone, G. Sesti, F. Perticone and A. Pujia, 2004. Relation of low bone mineral density and carotid atherosclerosis in postmenopausal women. Am. J. Cardiol., 94: 266-269.
106. Moon, J., B. Bandy and A.J. Davison, 1992. Hypothesis: Etiology of atherosclerosis and osteoporosis: are imbalances in the calciferol endocrine system implicated? J. Am. Coll. Nutr., 11: 567-583.
107. Moshage, H., 1997. Cytokines and the hepatic acute phase response. J. Pathol., 181: 257-266.
108. Munakata, M., N. Ito, T. Nunokawa and K. Yoshinaga, 2003. Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am. J. Hypertens., 16: 653-657.
109. Nabipour, I., B. Larijani, K. Vahdat, M. Assadi and S.M. Jafari et al., 2009. Relationships among serum receptor of nuclear factor-kB ligand, osteoprotegerin, high-sensitivity C-reactive protein and bone mineral density in postmenopausal women: Osteoimmunity versus osteoinflammatory. Menopause, 16: 950-955.
110. Nawawi, H., N.S. Osman, R. Annuar, B.A. Khalid and K. Yusoff, 2003. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolemia treated with atorvastatin. Atherosclerosis, 169: 283-291.
111. Niemann-Jonsson, A., P. Dimayuga, S. Jovinge, F. Calara, M.P. Ares, G.N. Fredrikson and J. Nilsson, 2000. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-α expression. Arterioscler. Thromb. Vasc. Biol., 20: 2205-2211.
112. Nikfar, S., R. Rahimi and M. Abdollahi, 2010a. A metaanalysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Clin Ther., 32: 1871-1888.
113. Nikfar, S., R. Rahimi and M. Abdollahi, 2010b. A systematic review on the efficacy of interferon β in relapsing remitting multiple sclerosis: Comparison of different formulations. Int. J. Pharmacol., 6: 638-644.
114. Oelzner, P., S. Franke, A. Muller, G. Hein and G. Stein, 1999. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford), 38: 841-847.
115. Ohmori, R., Y. Momiyama, H. Taniguchi, R. Takahashi, M. Kusuhara, H. Nakamura and F. Ohsuzu, 2003. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis, 170: 333-337.
116. Olmos, J.M., T. De Vega, L. Perera, J.A. Riancho, J.A. Amado and J. Gonzalez-Macias, 1999. Etidronate inhibits the production of IL-6 by osteoblast-like cells. Meth. Find. Exp. Clin. Pharmacol., 21: 519-522.
117. Omoigui, S., 2005. Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med. Hypotheses, 65: 559-569.
118. Orozco, P., 2004. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur. J. Epidemiol., 19: 1105-1112.
119. Papadopoulos, N.G., K. Georganas, V. Skoutellas, E. Konstantellos and G.P. Lyritis, 1997. Correlation of interleukin-6 serum levels with bone density in postmenopausal women. Clin. Rheumatol., 16: 162-165.
120. Papanicolaou, D.A., R.L. Wilder, S.C. Manolagas and G.P. Chrousos, 1998. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med., 128: 127-137.
121. Parhami, F., A.D. Marrow, J. Balucan, N. Leitinger and A.D. Watson et al., 1997. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Aterioscler. Thromb. Vasc. Biol., 17: 680-687.
122. Parhami, F., S. Jackson, Y. Tintut, V. Le, J.P. Balucan, M. Territo and L.L. Demer, 1999. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J. Bone Miner. Res., 14: 2067-2078.
123. Parhami, F., A. Garfinkel and L.L. Demer, 2000. Role of lipids in osteoporosis. Aterioscler. Thromb. Vasc. Biol., 20: 2346-2348.
124. Parhami, F., 2003. Possible role of oxidized lipids in osteoporosis: Could hyperlipidemia be a risk factor: Prostaglandins Leukot Essent. Fatty Acids, 68: 373-378.
125. Pasco, J.A., M.A. Kotowicz, M.J. Henry, G.C. Nicholson, H.J. Spilsbuiy, J.D. Box and H.G. Schneider, 2006. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA., 296: 1353-1355.
126. Pennisi, P., S.S. Signorelli, S. Riccobene, G. Celotta, L. Di Pino, T. La Malfa and C.E. Fiore, 2004. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos. Int., 15: 389-395.
127. Piatt, M.O., R.F. Ankeny, G.P. Shi, D. Weiss, J.D. Vega, W. R Taylor and H. Jo, 2007. Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in humanatherosclerosis. Am. J. Physiol. Heart Circ. Physiol., 292: 1479-1486.
128. Pratico, D., J. luliano, A. Mauriello, L. Spagnoli and J. A. Lawson et al., 1997. Localization of distinct F2-isoprostanes in human atherosclerosis lesions. J. Clin Invest., 100: 2028-2034.
129. Price, P.A., S.A. Faus and M.K. Williamson, 2001. Biphosphonates alendronate and ibandronate inhibit arteiy calcification at doses comparable to those that inhibit bone resorption. Arterioscler. Thromb. Vasc. Biol., 21: 817-824.
130. Rahimi, R., S. Nikfar, B. Larijani and M. Abdollahi, 2005. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother., 59: 365-373.
131. Rahimi, R, S. Ghiasi, H. Azimi, S. Fakhari and M. Abdollahi, 2010. A review of the herbal phosphodiesterase inhibitors: future perspective of new drugs. Cytokine, 49: 123-129.
132. Raisz, L.G., 1999. Osteoporosis: Current approaches and future prospects in diagnosis, pathogenesis and management. J. Bone Miner. Metab., 17: 79-89.
133. Reid, I.R., M.C. Evans, R. Ames and D.J. Wattle, 1991. The influence of osteophytes and aortic calcification on spinal mineral density in postmenopausal women. J. Clin. Endocrinol. Metab., 72: 1372-1374.
134. Rendina, D., L. Postiglione, P. Vuotto, F.G. Numis and G. Di Domenico et al., 2002. Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone. Clin. Exp. Rheumatol., 20: 359-364.
135. Rezaie, A., R.D. Parker and M. Abdollahi, 2007. Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause. Dig. Dis. Sci., 52: 2015-2021.
136. Ridker, P.M., N. Rifai, M. Pfeffer, F. Sacks, S. Lepage and E. Braunwald, 2000. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation, 101: 2149-2153.
137. Roggia, C., Y. Gao, S. Cenci, M.N. Weitzmann, G. Toraldo, G. Isaia and R. Pacifici, 2001. Up-regulation of TNF producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA., 98: 13960-13965.
138. Ross, R., 1999. Atherosclerosis: An inflammatory disease. N. Eng. J. Med., 340: 115-126.
139. Rostand, S.G. and T.B. Drueke, 1999. Parathyroid hormone, Vitamin D and cardiovascular disease in chronic renal failure. Kidney Int., 56: 383-392.
140. Salamone, L.M., T. Whiteside, D. Friberg, R.S. Epstein, L.H. Kuller and J.A. Cauley, 1998. Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Clacif. Tissue Int., 63: 466-470.
141. Salari, P. and M. Abdollahi, 2009. Controversial effects of non-steroidal anti-inflammatory drugs on bone: A review. Inflamm. Allergy Drug Targets, 8: 169-175.
142. Salari, P., A. Rezaie, B. Larijani and M. Abdollahi, 2008a. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med. Sci. Monitor, 14: RA37-44.
143. Salari, P., B. Larijani and M. Abdollahi, 2008b. Association of hyperhomocysteinemia with osteoporosis: A systematic review. Therapy, 5: 215-222.
144. Samokhin, A.O., A. Wong, P. Saftig and D. Bromme, 2008. Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice. Atherosclerosis, 200: 58-68.
145. Scheidt-Nave, C., H. Bismar, G. Leidig-Bruckner, G. Woitge, M.J. Seibel, R. Ziegler and J. Pfeilschifter, 2001. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J. Clin. Endocrinol. Metab., 86: 2032-2042.
146. Schett, G., S. Kiechl, S. Weger, A. Pederiva and A. Mayr et al., 2006. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch. Intern. Med., 166: 2495-2501.
147. Schoppet, M., K.T. Preissner and L.C. Hofbauer, 2002. RANK ligand and osteoprotegerin: Paracrine regulators of b one metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol., 22: 549-553.
148. Schoppet, M., A.M. Sattler, J.R. Schaefer, M. Herzum, B. Maisch and L.C. Hofbauer, 2003. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. Metab., 88: 1024-1028.
149. Schreyer, S.A., C.M. Vick and R.C. LeBoeuf, 2002. Loss of lymphotoxin-α but not tumor necrosis factor-α reduces atherosclerosis in mice. J. Biol. Chem., 277: 12364-12368.
150. Schulz, E., K. Arfai, X. Liu, J. Sayre and V. Gilsanz, 2004. Aortic calcification and the risk of osteoporosis and fractures. J. Clin. Endocrinol. Metab., 89: 4246-4253.
151. Seo, S.K., S. Cho, H. Y. Kim, Y.S. Choi, K.H. Park, D.J. Cho and B.S. Lee, 2009. Bone mineral density, arterial stiffness and coronary atherosclerosis in healthy postmenopausal women. Menopause, 16: 937-943.
152. Shaffer, J.R., C.M. Kammerer, D.L. Rainwater, D.H. O'Leary, J.M. Bruder, R.L. Bauer and B.D. Mitchell, 2007. Decreased bone mineral density is correlated with increased subclinical atherosclerosis in older but not younger, Mexican American women and men: The san antonio family osteoporosis study. Calcif. Tissue Int., 81: 430-441.
153. Sharif, P.S. and M. Abdollahi, 2010. The role of platelets in bone remodelling. Inflamm. Allerg. Drug. Targets, 9: 393-399.
154. Sharif, P.S., M. Asalforoush, F. Ameri, B. Larijani and M. Abdollahi, 2010a. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: A randomized clinical trial. Age, 32: 179-186.
155. Sharif, P.S., S. Nikfar and M. Abdollahi, 2010b. Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: A meta-analysis. Age, 32: 179-186.
156. Sharif, P.S. and M. Abdollahi, 2011. A systematic review on the relation between use of statins and osteoporosis. Int. J. Pharmacol., 7: 180-188.
157. Sharif, P.S., M. Abdollahi and B. Larijani, 2011. Current, new and future treatments of osteoporosis. Rheumatol. Int., 31: 289-300.
158. Suganami, T., J. Nishida and Y. Ogawa, 2005. A paracrine loop between adipocytes and macrophages aggravates inflammatoiy changes: Role of free fatty acids and tumor necrosis factor a. Arterioscler. Thromb. Vasc. Biol., 25: 2062-2068.
159. Sukhova, G.K., G.P. Shi, D.I. Simon, H.A. Chapman and P. Libby, 1998. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smoth muscle cells. J. Clin. Invest., 102: 576-583.
160. Sumino, H., S. Ichikawa, S. Kasama, T. Takahashi and H. Kumakura et al., 2006. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas, 55: 212-218.
161. Sun, D., A. Krishnan, K. Zaman, R. Lawrence, A. Bhattacharya and G. Fernandes, 2003. Dietary n-3 fatly acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J. Bone. Mine. Res., 18: 1206-1216.
162. Sweatt, A., D.C. Sane, S.M. Hutson and R. Wallin, 2003. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J. Thromb. Haemost., 1: 178-185.
163. Tabibzadeh, S.S., U. Santhanam, P.B. Sehgal and L.T. May, 1989. Cytokine induced production of IFN-β 2/TL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol 17β. J. Immunol., 142: 3134-3139.
164. Takemoto, M., K. Yokote, M. Nishimura, T. Shigematsu and T. Hasegawa et al., 2000. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler. Thromb. Vasc. Biol., 20: 624-628.
165. Tanko, L.B., Y.Z. Bagger and C. Christiansen, 2003. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif. Tissue Int., 73: 15-20.
166. Tanko, L.B., C. Christiansen, D.A. Cox, M.J. Geiger, M.A. McNabb and S.R. Cummings, 2005. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone Miner Res., 20: 1912-1920.
167. Tintut, Y., F. Parhami, A. Tsingotjidou, S. Tetradis, M. Territo and L.L. Demer, 2002. 8-Isoprostaglandin E2 enhances receptor-activated NF κB ligand (RANKL)-dependent osteoclastic potential of marrow hematopietic precursors via the cAMP pathway. J. Biol. Chem., 277: 14221-14226.
168. Tobin, J.F. and A.J. Celeste, 2006. Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease. Drug Discov. Today., 11: 405-411.
169. Towler, D.A., 2008. The osteogenic-angiogenic interface: Novel insights into the biology of bone formation and fracture repair. Curr. Osteoporos. Rep., 6: 67-71.
170. Troen, B.R., 2003. Molecular mechanisms underlying osteoclast formation and activation. Exp. Gerontol., 38: 605-614.
171. Uyama, O., Y. Yoshimoto, Y. Yamamoto and A. Kawai, 1997. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke, 28: 1730-1732.
172. Van der Klift, M., H.A.P. Pols, A.E. Hak, J.C.M. Witteman, A. Hofman and C.E.D.H. de Laet, 2002. Bone mineral density and the risk of peripheral arterial disease: The rotterdam study. Calcif. Tissue Int., 70: 443-449.
173. Vandenabeele, P., W. Declercq, R. Beyaert and W. Fiers, 1995. Two tumor necrosis factor receptors: Strudcture and function. Trends Cell. Biol., 5: 392-399.
174. Vattikuti, R. and D.A. Towler, 2004. Osteogenic regulation of vascular calcification: An early perspective. Am. J. Physiol. Endocrinol. Metab., 286: E686-E696.
175. Verit, F.F., H. Celik, P. Yazgan, O. Erel and I. Geyikli, 2006. Paraoxonase-1 activity as a marker of atherosclerosis is not associated with low bone mineral density in healthy postmenopausal women. Arch. Gynecol. Obstet., 275: 353-359.
176. Vermeer, C. and L. Braam, 2001. Role of K vitamins in the regulation of tissue calcification. J. Bone. Miner. Metab., 19: 201-206.
177. Vik, A., E.B. Mathiesen, A.T.W. Noto, B. Sveinbjornsson, J. Brox and J.B. Hansen, 2007. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis, 191: 128-134.
178. Vogt, M.T., J.A. Cauley, L.H. Kuller and M.C. Nevitt, 1997a. Bone mineral density and blood flow to the lower extremities: The study of osteoporotic fractures. J. Bone. Miner. Res., 12: 283-289.
179. Vogt, M.T., R. San Valentin, K. Y. Forrest, M.C. Nevitt and J.A. Cauley, 1997b. Bone mineral density and aortic calcification: the study of osteoporotic fractures. J. Am. Geπatr. Soc., 45: 140-145.
180. Von der Recke, P., M.A. Hansen and C. Hassager, 1999. The association between low bone mass at the menopause and cardiovascular mortality. Am. J. Med., 106: 273-278.
181. Von der Thusen, J.H., J. Kuiper, T.J.C. van Berkel and E.A.L. Biessen, 2003. Interleukins in atherosclerosis: Molecular pathways and therapeutic potential. Pharmacol. Rev., 55: 133-166.
182. Wajant, H., K. Pfizenmaier and P. Scheurich, 2003. Tumor necrosis factor signaling. Cell Death Differ., 10: 45-65.
183. Walsh, M.C. and Y. Choi, 2003. Biology of the TRANCE axis. Cytokine Growth Factor Rev., 14: 251-263.
184. Weber, C., A. Zernecke and P. Libby, 2008. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat. Rev. Immunol., 8: 802-815.
185. Weinhold, B. and U. Ruther, 1997. Interleukin-6-dependent and-independent regulation of the human c_reactive protein gene. Biochem. J., 327: 425-429.
186. Witztum, J.L. and D. Steinberg, 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest., 88: 1785-1792.
187. Xanthoulea, S., M.J.J. Gijbels, I. van der Made, H. Mujcic and M. Thelen et al., 2008. P55 Tumor necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice. Cardiovasc. Res., 80: 309-318.
188. Yamada, Y., F. Ando, N. Niino, T. Miki and H. Shimokata, 2003. Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese. J. Hum. Genet., 48: 469-475.
189. Yamashina, A., H. Tomiyama, T. Arai, K. Hirose and Y. Koji et al., 2003. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens. Res., 26: 615-622.
190. Yoshida, N., S. Ikemoto, K. Narita, K. Sugimura and S. Wada et al., 2002. Interleukin-6, tumor necrosis factor alpha and interleukin-1 beta in patients with renal cell carcinoma. Br. J. Cancer, 86: 1396-1400.
191. Yousefzadeh, G., B. Larijani, B. Mohammadirad R. Heshmat, G. Dehghan, R. Rahimi and M. Abdollahi, 2006. Determination of oxidative stress status and concentration of TGF-βl in the blood and saliva of osteoporotic subjects. Ann. N. Y. Acad. Sci., 1091: 142-150.
192. Yudkin, J.S., C.D. Stehouwer, J.J. Emeis and S.W. Coppack, 1999. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol., 19: 972-978.
193. Yudkin, J.S., M. Kumari, S.E. Humphries and V. Mohamed-Ali, 2000. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis, 148: 209-214.
194. Yura, T., M. Fukunaga, R. Khan, G.N. Nassar, K.F. Badr and A. Montero, 1999. Free-radical-generated F2-isoprostane stimulate cell proliferation and endothelin-1 expression on endothelial cells. Kidney. Int., 56: 471-478.
195. Zheng, S.X., Y. Vrindts, M. Lopez, D. De Groote and P.F. Zangerle et al., 1997. Increase in cytokine production (IL-1 β, IL-6, TNF-α but not IFN-γ, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas, 26: 63-71.